SCHEMBL20132907

SCHEMBL20132907

CC(C)(C)OC(=O)N1CC(OCCCOCCCO[C@H]2C[C@H](OCc3ccccc3)C2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 3/20 0.45
WDR77 Q9BQA1 3/20 0.45
JAK2 O60674 1/20 0.45
JAK1 P23458 1/20 0.45
ABCB1 P08183 1/20 0.43
STS P08842 1/20 0.42
GPR119 Q8TDV5 2/20 0.41
USP30 Q70CQ3 1/20 0.40
KLK7 P49862 1/20 0.40
BCHE P06276 1/20 0.40
BACE1 P56817 1/20 0.40
BACE2 Q9Y5Z0 1/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
NAMPT P43490 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RORC P51449 1/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
YAP1 P46937 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20132906 0.92 L3MBTL1 (0.47) PRMT5WDR77JAK2JAK1STS
SCHEMBL20129209 0.91 L3MBTL1 (0.47) PRMT5WDR77JAK2JAK1STS
SCHEMBL22906672 0.89 L3MBTL1 (0.51) PRMT5WDR77JAK2JAK1STS
SCHEMBL28959331 0.89 L3MBTL1 (0.50) PRMT5WDR77JAK2JAK1STS
SCHEMBL20133160 0.89 STS (0.47) PRMT5WDR77JAK2JAK1STS
SCHEMBL9938446 0.88 PRMT5 (0.51) PRMT5WDR77JAK2JAK1ABCB1
SCHEMBL22906774 0.87 PRMT5 (0.44) PRMT5WDR77JAK2JAK1ABCB1
SCHEMBL22907262 0.86 JAK2 (0.41) PRMT5WDR77JAK2JAK1ABCB1
SCHEMBL27140032 0.86 JAK2 (0.41) PRMT5WDR77JAK2JAK1ABCB1
SCHEMBL2387673 0.84 PRMT5 (0.47) PRMT5WDR77JAK2JAK1STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 WO disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN PRMT5 584/4885WDR77 1631/4885JAK2 2782/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 PRMT5 547/4885WDR77 1688/4885JAK2 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.